June 2021 when there was the greatest deluge of severe cases. Dr Raja Dhar, heading the Pulmonology department at the CMRI Hospitals in Kolkata, was the Principle Investigator and oversaw the entire study process. There were 387 participants who participated in the study. 77 developed critical diseases needing ICU admission. The arm in which doxycycline was given had an absolute and relative risk reduction compared to the arm in which did not have doxycycline. The reduction was significant by statistical analysis. Doxycycline was also well tolerated and not a single patient required stoppage of treatment due to adverse events. The conclusion was that in hospitalized COVID-19 patients, doxycycline was a safe and inexpensive treatment widely available throughout the globe and it reduced ICU admissions when added to the standard of care. Dr Dhar stated that the trial was carried out in the midst of the deadly second Covid- 19 wave in India and circumstances could not have been more challenging. This has been an excellent pragmatic and very friendly collaboration by experts across multiple continents and they are greatly encouraged by the findings of this well-known and widely available antibiotic.